" /> Synthesis, Biological Evaluation and invitro stability of New Schiff Bases of cytarabine Mutual Prodrugs

IJCRAR is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCRAR Articles.

INDEXED IN INDEX COPERNICUS - ICI Journals Master List 2016 - IJCRAR--ICV 2016: 81.15 For more details click here

Abstract            Volume:4  Issue-2  Year-2016         Original Research Articles


Online ISSN : 2347 - 3215
Issues : 12 per year
Publisher : Excellent Publishers
Email : editorijcret@gmail.com

Synthesis, Biological Evaluation and invitro stability of New Schiff Bases of cytarabine Mutual Prodrugs
Mohsin O.Mohammed*
Department of Chemistry, College of Science, Kirkuk University, Kirkuk, Iraq
*Corresponding author
Abstract:

Cytarabine (Ara-C) is a chemotherapeutic agent predominately used for the treatment of acute myeloid leukemia and lymphoblastic leukemia. In this work, a new method of synthesis seven Ara-C Schiff base derivatives and study their effect on inhibiting the growth on certain pathogenic bacteria were described. Almost all analysed compounds inhibit the health of the studied bacteria significantly. Synthesised compounds were subjected to a stability study in phosphate buffer (0.2 M, pH 7.4) and in KCl/HCl buffer (0.2 M, pH 1.2) at different time intervals (0 – 240 min) incubated at 37°C. This revealed that all synthesised compounds are significantly stable and have longer t 1/2 in comparison with Ara-C. In vitro cytotoxicity results showed that the new prodrug had a much less toxicity and may be considered for further biological screening and application trial.

Keywords: Cytarabine,Leukaemia,Schiff base,Nucleoside
Download this article as Download

How to cite this article:

Mohsin O.Mohammed. 2016. Synthesis, Biological Evaluation and invitro stability of New Schiff Bases of cytarabine Mutual Prodrugs.Int.J.Curr.Res.Aca.Rev. 4(2): 89-98
doi: http://dx.doi.org/10.20546/ijcrar.2016.402.011
Copyright: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike license.